🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Perioperative Transcranial Photobiomodulation and Delayed Neurocognitive Recovery in Older Patients

RecruitingNAAges 65 Years - anyAllPeking University First Hospital
NCT07736092 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Delayed neurocognitive recovery is a common neurocognitive complication in older patients after surgery, especially those with preoperative neurocognitive decline. Transcranial photobiomodulation therapy is a novel neuromodulation technique using transcranial low-power light to modulate brain biological functions. This technique has been used to treat various neurological or psychiatric conditions, including ischemic stroke, traumatic brain injury, and major depression. This study is designed to explore whether using transcranial photobiomodulation therapy during the perioperative period can reduce the incidence of delayed neurocognitive recovery in older patients with pre-existing neurocognitive impairment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged 65 years or older. * Preoperative Mini-Mental State Examination (MMSE) \<27. * Scheduled to undergo non-cardiac, non-neurosurgical surgery under general anesthesia, with an expected surgical duration \>1 hour. * Planned hospital stay of at least 1 day before surgery and at least 2 days after surgery. Exclusion Criteria: * Communication barriers before surgery due to coma, severe dementia, or language disorders. * History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis, or delirium before surgery. * History of brain injury, tumors, or surgery, or intracranial metal implants, or skin or soft tissue injuries on the head or face. * History of ischemic or hemorrhagic stroke within 3 months before surgery. * An American Society of Anesthesiologists class ≥ IV. * Enrolled in other interventional studies. * Other conditions deemed unsuitable for study participation.
💊

What it tests

  • Transcranial photobiomodulation therapy
  • Transcranial pseudo-photobiomodulation
📍

Where

1 site
Peking University First Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy